Second- and further-line therapy with erlotinib in patients with advanced non-small-cell lung cancer in daily clinical practice.

Biomed Res Int · 2014 · PMC4084583 · PMID 25028671

Europe PMC DOI

hedged sentence

0.1460

closest p · 2.9× alpha

0.1460

boldest claim

The sentences

a nonsignificant trendP = 0.146not close (p > 0.1)

In patients with an interruption of treatment due to side effects, a nonsignificant trend for a lower rate of progression was encountered (DCR with interruption 82.4%, without 60.7%, P = 0.146).

also in 5,406 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.